Q1 Earnings Estimate for CASI Issued By HC Wainwright

CASI Pharmaceuticals Inc. (NASDAQ:CASI) – HC Wainwright issued their Q1 2026 EPS estimates for CASI Pharmaceuticals in a note issued to investors on Wednesday, September 3rd. HC Wainwright analyst S. Lee anticipates that the biotechnology company will post earnings of ($0.37) per share for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. HC Wainwright also issued estimates for CASI Pharmaceuticals’ Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.36) EPS and Q4 2026 earnings at ($0.36) EPS.

CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings data on Friday, August 29th. The biotechnology company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.39). CASI Pharmaceuticals had a negative return on equity of 1,844.13% and a negative net margin of 148.55%.The company had revenue of $4.18 million for the quarter, compared to analyst estimates of $6.28 million.

Separately, Wall Street Zen began coverage on shares of CASI Pharmaceuticals in a research report on Thursday, May 22nd. They set a “hold” rating for the company. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, CASI Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $4.00.

CASI Pharmaceuticals Price Performance

NASDAQ CASI opened at $2.34 on Thursday. The company has a market capitalization of $28.78 million, a PE ratio of -0.81 and a beta of 0.77. The company has a fifty day moving average of $1.74 and a 200 day moving average of $1.90. CASI Pharmaceuticals has a 1 year low of $1.09 and a 1 year high of $7.67.

Institutional Trading of CASI Pharmaceuticals

A hedge fund recently raised its stake in CASI Pharmaceuticals stock. Woodline Partners LP boosted its holdings in shares of CASI Pharmaceuticals Inc. (NASDAQ:CASI) by 226.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 99,690 shares of the biotechnology company’s stock after acquiring an additional 69,158 shares during the period. Woodline Partners LP owned 0.64% of CASI Pharmaceuticals worth $282,000 at the end of the most recent reporting period. 22.23% of the stock is currently owned by institutional investors.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.